Search

Your search keyword '"D'Humieres, T"' showing total 16 results
Start Over Author "D'Humieres, T"
16 results on '"D'Humieres, T"'

1. Clinical picture, outcomes and predictors of relapse in eosinophilia-associated coronary vasospasm: data from a European multicentric study

Author

Huang, F, Khellaf, L, Lefevre, G, Berti, A, D'Humieres, T, Sionis, A, Sole, A, Bello, F, Bermeo Garrido, J, Crickx, E, Delvino, P, Emmi, G, Gaillet, A, Garcia, G, Gavand, P, George, J, Gilles, F, Golden, C, de Groote, P, Guffroy, A, Martis, N, Monti, S, Mourlanette, P, Pineton de Chambrun, M, Prunier, F, Regola, F, Seret, G, Terrier, B, Trefond, L, Souteyrand, G, Varenne, O, Zilio, F, Haziza, F, Benamer, H, Kahn, J, Vallee, A, Groh, M, Huang F., Khellaf L. R., Lefevre G., Berti A., d'Humieres T., Sionis A., Sole A. A., Bello F., Bermeo Garrido J. A., Crickx E., Delvino P., Emmi G., Gaillet A., Garcia G., Gavand P. -E., George J. -L., Gilles F., Golden C., de Groote P., Guffroy A., Martis N., Monti S., Mourlanette P., Pineton de Chambrun M., Prunier F., Regola F., Seret G., Terrier B., Trefond L., Souteyrand G., Varenne O., Zilio F., Haziza F., Benamer H., Kahn J. -E., Vallee A., Groh M., Huang, F, Khellaf, L, Lefevre, G, Berti, A, D'Humieres, T, Sionis, A, Sole, A, Bello, F, Bermeo Garrido, J, Crickx, E, Delvino, P, Emmi, G, Gaillet, A, Garcia, G, Gavand, P, George, J, Gilles, F, Golden, C, de Groote, P, Guffroy, A, Martis, N, Monti, S, Mourlanette, P, Pineton de Chambrun, M, Prunier, F, Regola, F, Seret, G, Terrier, B, Trefond, L, Souteyrand, G, Varenne, O, Zilio, F, Haziza, F, Benamer, H, Kahn, J, Vallee, A, Groh, M, Huang F., Khellaf L. R., Lefevre G., Berti A., d'Humieres T., Sionis A., Sole A. A., Bello F., Bermeo Garrido J. A., Crickx E., Delvino P., Emmi G., Gaillet A., Garcia G., Gavand P. -E., George J. -L., Gilles F., Golden C., de Groote P., Guffroy A., Martis N., Monti S., Mourlanette P., Pineton de Chambrun M., Prunier F., Regola F., Seret G., Terrier B., Trefond L., Souteyrand G., Varenne O., Zilio F., Haziza F., Benamer H., Kahn J. -E., Vallee A., and Groh M.

Published
2024

2. Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality

Author

Lezoualc'h, F, Badimon, L, Baker, H, Bernard, M, Czibik, G, De Boer, RA, D'Humieres, T, Kergoat, M, Kowala, M, Rieusset, J, Vilahur, G, Detrait, M, Watson, C, and Derumeaux, GA

Subjects
Heart Failure, Type 2 diabetes mellitus, Organ-to-organ interaction, Insulin resistance, Diabetic cardiomyopathy
Abstract

Diabetic cardiomyopathy (CM), occurring in the absence of hypertension, coronary artery disease, and valvular or congenital heart disease, is now recognized as a distinct, multifactorial disease leading to ventricular hypertrophy and abnormal myocardial contractility that correlates with an array of complex molecular and cellular changes. Animal models provide the unique opportunity to investigate mechanistic aspects of diabetic CM, but important caveats exist when extrapolating findings obtained from preclinical models of diabetes to humans. Indeed, animal models do not recapitulate the complexity of environmental factors, most notably the duration of the exposure to insulin resistance that may play a crucial role in the development of diabetic CM. Moreover, most preclinical studies are performed in animals with uncontrolled or poorly controlled diabetes, whereas patients tend to undergo therapeutic intervention. Finally, whilst type 2 diabetes mellitus prevalence trajectory mainly increases at 40- < 75 years (with a currently alarming increase at younger ages, however), it is a legitimate concern how closely rodent models employing young animals recapitulate the disease developing in old people. The aim of this review is to identify the current limitations of rodent models and to discuss how future mechanistic and preclinical studies should integrate key confounding factors to better mimic the diabetic CM phenotype.

Published
2022

14. Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants.

Author

Touboul O, Algalarrondo V, Oghina S, Elbaz N, Rouffiac S, Hamon D, Extramiana F, Gandjbakhch E, D'Humieres T, Marijon E, Dhanjal TS, Teiger E, Damy T, and Lellouche N

Subjects
Humans, Male, Aged, Female, Electric Countershock adverse effects, Electric Countershock methods, Atrial Flutter complications, Atrial Flutter therapy, Atrial Fibrillation complications, Atrial Fibrillation therapy, Thrombosis etiology, Heart Diseases, Amyloidosis complications, Amyloidosis diagnosis, Amyloidosis therapy
Abstract

Aims: Atrial fibrillation (AF)/atrial flutter is common during cardiac amyloidosis (CA). Electrical cardioversion (EC) is a strategy to restore sinus rhythm (SR). However, left atrial thrombus (LAT) represents a contraindication for EC. CA patients with AF/atrial flutter have a high prevalence of LAT. We aimed to evaluate EC characteristics, LAT prevalence and risk factors, and AF/atrial flutter outcome in CA patients undergoing EC, predominantly treated with direct oral anticoagulants (DOACs)., Methods and Results: All patients with CA and AF/atrial flutter referred for the first time to our national referral centre of amyloidosis for EC from June 2017 to February 2021 were included in this study. In total, 66 patients (median age 74.5 [70;80.75] years, 67% male) were included with anticoagulation consisted of DOAC in 74% of cases. All patients underwent cardiac imaging before EC to rule out LAT. EC was cancelled due to LAT in 14% of cases. Complete thrombus resolution was observed in only 17% of cases. The two independent parameters associated with LAT were creatinine [hazard ratio (HR) = 1.01; confidence interval (CI) = 1.00-1.03, P = 0.036] and the use of antiplatelet agents (HR = 13.47; CI = 1.85-98.02). EC acute success rate was 88%, and we observed no complication after EC. With 64% of patients under amiodarone, AF/atrial flutter recurrence rate following EC was 51% after a mean follow-up of 30 ± 27 months., Conclusions: Left atrial thrombus was observed in 14% of CA patients listed for EC and mainly treated with DOAC. The acute EC success rate was high with no complication. The long-term EC success rate was acceptable (49%)., (© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2022
Full Text
View/download PDF

15. Three-Dimensional Inferior Vena Cava for Assessing Central Venous Pressure in Patients with Cardiogenic Shock.

Author

Huguet R, Fard D, d'Humieres T, Brault-Meslin O, Faivre L, Nahory L, Dubois-Randé JL, Ternacle J, Oliver L, and Lim P

Subjects
Aged, Artifacts, Blood Pressure Determination, Female, Humans, Male, Prospective Studies, Reproducibility of Results, Echocardiography, Three-Dimensional, Shock, Cardiogenic physiopathology, Shock, Cardiogenic therapy, Vena Cava, Inferior diagnostic imaging
Abstract

Background: The inferior vena cava (IVC) has a complex three-dimensional (3D) shape, but measurements used to estimate central venous pressure (CVP) remain based on two-dimensional (2D) echocardiographic imaging. The aim of this study was to investigate the accuracy of IVC size and collapsibility index obtained by 3D echocardiography for assessing CVP in patients with cardiogenic shock., Methods: Eighty consecutive echocardiographic examinations performed in 33 patients (mean age, 72 ± 15 years; mean left ventricular ejection fraction, 19 ± 10%) admitted for cardiogenic shock were prospectively included. Two-dimensional and 3D images of the IVC were acquired simultaneously with invasive measurement of CVP, both at rest and during a sniff test. IVC diameters, 3D IVC area, and IVC collapsibility index (IVCCI) were assessed. The eccentricity index was computed from 3D data as the ratio of maximum to minimum IVC diameter. A cutoff value of 10 mm Hg for CVP defined patients with euvolemic hemodynamic status., Results: At rest, IVC diameter averaged 23 ± 7 mm by 2D imaging and 25 ± 8 × 19 ± 7 mm by 3D imaging. The IVC had an eccentric shape (eccentricity index = 1.3) that increased when CVP was ≤10 mm Hg and during the sniff test (P < .001). IVC measurements by 2D and 3D imaging were correlated with CVP. The best correlation was obtained with IVCCI derived from 2D diameters (R = -0.69) and 3D areas (R = -0.82). Using a cutoff value of 50% for IVCCI, 11 examinations were misclassified by 2D imaging and only one by 3D imaging. Inter- and intraobserver reproducibility for IVC area was 7 ± 6% and 5 ± 3%, respectively., Conclusions: In patients with cardiogenic shock, IVCCI from area by 3D echocardiography is reproducible and accurate to evaluate CVP., (Copyright © 2018 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.)

Published
2018
Full Text
View/download PDF

16. Left ventricular dyssynchrony and 2D and 3D global longitudinal strain for differentiating physiological and pathological left ventricular hypertrophy.

Author

Ternacle J, Bremont C, d'Humieres T, Faivre L, Doan HL, Gallet R, Oliver L, Dubois-Randé JL, and Lim P

Subjects
Adult, Aged, Area Under Curve, Biomechanical Phenomena, Cardiomyopathy, Hypertrophic physiopathology, Chi-Square Distribution, Diagnosis, Differential, Football, Humans, Hypertrophy, Left Ventricular physiopathology, Image Interpretation, Computer-Assisted, Logistic Models, Middle Aged, Observer Variation, Predictive Value of Tests, Prognosis, ROC Curve, Reproducibility of Results, Retrospective Studies, Stress, Mechanical, Ventricular Dysfunction, Left physiopathology, Young Adult, Cardiomegaly, Exercise-Induced, Cardiomyopathy, Hypertrophic diagnostic imaging, Echocardiography, Doppler, Echocardiography, Three-Dimensional, Hypertrophy, Left Ventricular diagnostic imaging, Myocardial Contraction, Ventricular Dysfunction, Left diagnostic imaging, Ventricular Function, Left
Abstract

Background: Diagnosis of hypertrophic cardiomyopathy (HCM) in athletes can be challenging., Aims: To ascertain parameters that differentiate patients with HCM from athletes with moderate left ventricular (LV) hypertrophy (LVH 13-15mm)., Methods: We retrospectively included 100 men: 50 elite rugby players (25 with moderate LVH and 25 with no LVH), 25 patients with HCM and moderate LVH and 25 controls. LV dyssynchrony was defined as the standard deviation of time to peak 2D longitudinal strain (16-segment model) and global strain components were computed from two- (2D) and three-dimensional (3D) speckle tracking., Results: 2D global longitudinal strain (GLS) (18±2% vs. 19±2%) and various 3D strain components were similar in athletes with moderate LVH and controls, while LV volumes and dyssynchrony (39±8 vs. 31±9ms; P<0.001) were greater in athletes with moderate LVH. The accuracy for differentiating patients with HCM from athletes ranged between 0.57 and 0.92 for various markers, with the best obtained for LV dyssynchrony (AUC=0.92;>48ms had sensitivity=83%, specificity=89%). Binary logistic regression showed that accuracy was improved when LV dyssynchrony was combined with 2D GLS. HCM was excluded when 2D GLS was preserved (>18%) and there was no LV dyssynchrony (>48ms) and only patients with HCM had reduced longitudinal strain and LV dyssynchrony., Conclusions: LV dyssynchrony combined with GLS can be used to differentiate athletes with moderate LVH from patients with HCM., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results